Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P
about
Novel perspectives on mucormycosis: pathophysiology, presentation, and management.Mucormycosis, pseudallescheriasis, and other uncommon mold infectionsMelanized fungi in human diseaseRecent advances in the management of mucormycosis: from bench to bedsidePharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infectionsMALDI-TOF mass spectrometry: an emerging technology for microbial identification and diagnosisIn vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs.Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimenA role for the unfolded protein response (UPR) in virulence and antifungal susceptibility in Aspergillus fumigatus.Susceptibility of filamentous fungi to voriconazole tested by two microdilution methodsCorrelation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results.International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole.Recent advances in the treatment of mucormycosis.Posaconazole as salvage therapy for zygomycosis.Fatal pneumonia caused by Penicillium digitatum: a case report.Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infectionMALDI-TOF-MS-based species identification and typing approaches in medical mycology.Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers.Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis modelInternational surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003).Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase.Itraconazole--perspectives for the management of invasive aspergillosis.Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs.Voriconazole in the management of nosocomial invasive fungal infections.Antifungal wound penetration of amphotericin and voriconazole in combat-related injuries: case report.Molecular epidemiology and in-vitro antifungal susceptibility of Aspergillus terreus species complex isolates in Delhi, India: evidence of genetic diversity by amplified fragment length polymorphism and microsatellite typingSystemic antifungal therapy: new options, new challenges.Solitary embolic cutaneous aspergillosis in the immunocompromised patient with acute myelogenous leukemia - a propos another case caused by Aspergillus flavus.Invasive aspergillosis in patients with hematologic malignancies.Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.Changing strategies for the management of invasive fungal infections.Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adultsChoices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients.In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection.Voriconazole: therapeutic review of a new azole antifungal.
P2860
Q24530554-1EA9BD9C-A8D4-448D-8130-AD4FC1ED9A7BQ24603297-2BD9D29C-F691-4ED0-A992-C84B61AF6F8DQ24633163-D7AE93D9-FD09-4604-BC3A-3BADDE93350BQ24642450-043488EC-CF53-45F2-BD12-887E80FAA4BCQ26771180-8DBAC887-ABC2-4FB2-9650-E1A86ABE0C9DQ26795481-0E9B0BAB-73DC-456A-AB94-8EB5F67025A7Q30453001-A5928323-E5D1-4BC9-BFC9-0C5F0E44211CQ33188045-C29B09B8-46BD-414B-B4BF-785F15B9B638Q33241227-49891A81-3FDC-4056-A0BE-41621B04917BQ33398514-7D06D545-F1B0-4EB8-B3EF-923BF406870CQ33592487-B882D7C4-2B86-4B86-92A9-CABF0DC2C203Q33826450-FABFE6F0-D737-410E-8EB9-0788E6DC6AF3Q34144184-37A3A02D-0C1F-4D7F-86A1-69A6674A9949Q34151084-A3747E0F-F0BD-4517-BAFD-10B2BEEE7F2CQ34161213-A088E557-35BA-4244-A2C9-66814200944FQ34301611-C6B7BE70-F28A-45F2-B28F-27DD0D938935Q34334809-2DA637A7-A22D-4B43-8986-0851E5D111C1Q34352014-EBD65F1F-C39C-4563-9CC0-88BAC174934FQ34529370-9B181F54-2739-4188-856A-6E9C102762D9Q34648517-B86F81D4-E289-4846-8634-12B90C7827D9Q34680655-9CB14824-864D-42E4-9C10-1269394A47F8Q34680661-F4121A2B-7CEC-4C74-BF30-8968ECE61E77Q34680675-DA1720CA-81A3-400C-86FF-FBA4F338B702Q34680831-F305D4F4-2055-417A-84F3-2BF0DBB766A8Q34823914-3839B8EE-9C01-4DBA-931D-3B894EAF5286Q35105394-E51257C1-EFF6-4B9B-85D8-92D78B49D04EQ35124469-3045484A-C7A4-46A9-9FDB-2E50784DF736Q35166823-227FD646-05CB-4E3C-88C7-0B617E71066DQ35493738-C5F071C7-D4E8-42A3-B665-763E5CEE5E18Q35579694-04651467-A427-4DF3-A8A0-0A76689599DAQ35585219-F130980A-84FF-4403-A062-D970D91DD065Q35592422-7000C365-1295-4774-A894-9A363FFDF50CQ35616161-AB008018-4E1B-40DF-90C3-2C1E7F21978AQ35635971-ECB0F7F5-C137-4C9F-AC77-D76F486B55ADQ35647678-F11750E1-0B2B-4E27-9549-782D3A49E81EQ35678997-CC0734D7-2B9A-4D0F-BCB8-51E63E169D80Q35685548-4A28AC2C-C925-40B6-BBB6-9BD3327005C8Q35833407-A7437FF6-2212-434F-B635-75496D5F0092Q35870651-31582B69-6270-4B10-8423-2D7767099A79Q35917452-983AA21D-684E-47E6-93A8-B1DE675FDE52
P2860
Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Antifungal activities of posac ...... Y Antimicrobial Surveillance P
@ast
Antifungal activities of posac ...... Y Antimicrobial Surveillance P
@en
Antifungal activities of posac ...... Y Antimicrobial Surveillance P
@nl
type
label
Antifungal activities of posac ...... Y Antimicrobial Surveillance P
@ast
Antifungal activities of posac ...... Y Antimicrobial Surveillance P
@en
Antifungal activities of posac ...... Y Antimicrobial Surveillance P
@nl
prefLabel
Antifungal activities of posac ...... Y Antimicrobial Surveillance P
@ast
Antifungal activities of posac ...... Y Antimicrobial Surveillance P
@en
Antifungal activities of posac ...... Y Antimicrobial Surveillance P
@nl
P2093
P2860
P3181
P1476
Antifungal activities of posac ...... Y Antimicrobial Surveillance P
@en
P2093
M A Pfaller
R J Hollis
S A Messer
SENTRY Participants Group
P2860
P304
P3181
P356
10.1128/AAC.46.4.1032-1037.2002
P407
P577
2002-04-01T00:00:00Z